| Literature DB >> 33944625 |
Harriet de Wit1, Anya K Bershad2, Charles Grob3.
Abstract
Despite substantial progress in the use of mind-altering drugs to treat psychiatric disorders, the psychological processes through which these drugs change mood or behavior are poorly understood. Controlled laboratory studies with well-defined psychological constructs are valuable to understand how these drugs manifest their therapeutic benefit. However, there are substantial methodological differences between clinical studies investigating therapeutic outcome and laboratory studies investigating the processes that might underlie the therapeutic effects. Here, we examine some of these differences using the example of 3,4-methylenedioxymethamphetamine (MDMA). We review differences in expectancies, social and physical context, participant characteristics, pharmacological factors, and outcome measures in studies with participants who do or do not have psychiatric diagnoses. We describe the challenges and opportunities in translating findings from laboratory studies to the clinic and identify ways to bridge the gap between these approaches.Entities:
Keywords: MDMA; Translational; mental disorders; research design
Mesh:
Substances:
Year: 2021 PMID: 33944625 DOI: 10.1177/02698811211015221
Source DB: PubMed Journal: J Psychopharmacol ISSN: 0269-8811 Impact factor: 4.153